Symbols / LABT $0.75 -13.11% Lakewood-Amedex Biotherapeutics, Inc.
LABT Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteLakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents that fight infections by disrupting microbial membranes. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Ratings
Current target
$0.75
Low
—
High
—
Mean
—
- symbol__ Stock Quote Price and Forecast - CNN Fri, 24 Apr 2026 15
- Lakewood-Amedex Biotherapeutics(LABT) Stock Options Chain | Quotes & News - Moomoo ue, 19 May 2026 19
- LABT Stock Price, Quote & Chart | LAKEWOOD-AMEDEX BIOTHERAPEUT (NASDAQ:LABT) - ChartMill Fri, 15 May 2026 07
- Lakewood-Amedex (LABT) Stock News & Updates - Stock Titan hu, 23 Apr 2026 07
- Lakewood-Amedex Stock Falls Despite Positive Nu-3 Manufacturing Update - Sahm ue, 19 May 2026 06
- LABT Stock Soars 50% After Nasdaq Debut – Retail Says $14 Is The Line In The Sand - Stocktwits Fri, 24 Apr 2026 11
- LABT - Finviz ue, 28 Apr 2026 10
- Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT" - PR Newswire hu, 23 Apr 2026 07
- LABT Stock Slides As Volatility Grips Thinly Capitalized Biotech - timothysykes.com Fri, 01 May 2026 07
- Why Rocket Lab Stock Zoomed 28.5% Higher In April - Yahoo Finance Sat, 02 May 2026 07
- LABT Stock Price and Chart — NASDAQ:LABT - TradingView Fri, 16 Jan 2026 21
- Lakewood-Amedex Biotherapeutics Inc (LABT) Stock Price, Quote, News & History - Benzinga hu, 23 Apr 2026 16
- LABT Stock Price, News & Analysis - Stock Titan hu, 23 Apr 2026 14
- [EFFECT] Lakewood-Amedex Biotherapeutics Inc. SEC Filing - Stock Titan hu, 14 May 2026 10
- Lakewood‑Amedex (LABT) registers 9.65M shares tied to Series C conversion - Stock Titan hu, 14 May 2026 20
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
3.77
-6.32%
|
4.03
-53.38%
|
8.64
|
| Research And Development |
|
1.26
-40.32%
|
2.10
-61.96%
|
5.53
|
| Selling General And Administration |
|
2.51
+31.05%
|
1.92
-38.08%
|
3.10
|
| General And Administrative Expense |
|
2.51
+31.05%
|
1.92
-38.08%
|
3.10
|
| Salaries And Wages |
|
1.08
+112.45%
|
0.51
-72.43%
|
1.85
|
| Other Gand A |
|
1.43
+1.52%
|
1.41
+20.60%
|
1.17
|
| Total Expenses |
|
3.77
-6.32%
|
4.03
-53.38%
|
8.64
|
| Operating Income |
|
-3.77
+6.32%
|
-4.03
+53.38%
|
-8.64
|
| Total Operating Income As Reported |
|
-3.77
+6.32%
|
-4.03
+53.38%
|
-8.64
|
| EBITDA |
|
-3.63
+23.35%
|
-4.73
+41.95%
|
-8.15
|
| Normalized EBITDA |
|
-3.63
+1.68%
|
-3.69
+54.75%
|
-8.15
|
| Reconciled Depreciation |
|
0.12
+1.17%
|
0.12
-1.98%
|
0.12
|
| EBIT |
|
-3.75
+22.75%
|
-4.85
+41.36%
|
-8.27
|
| Total Unusual Items |
|
0.00
+100.00%
|
-1.04
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
0.00
+100.00%
|
-1.04
|
0.00
|
| Special Income Charges |
|
0.00
+100.00%
|
-1.04
|
0.00
|
| Other Special Charges |
|
—
|
1.04
|
—
|
| Net Income |
|
-3.85
+20.76%
|
-4.86
+41.37%
|
-8.28
|
| Pretax Income |
|
-3.85
+20.76%
|
-4.86
+41.37%
|
-8.28
|
| Net Non Operating Interest Income Expense |
|
-0.08
-154.70%
|
0.14
-60.70%
|
0.35
|
| Interest Expense Non Operating |
|
0.10
+1917.62%
|
0.01
-50.00%
|
0.01
|
| Net Interest Income |
|
-0.08
-154.70%
|
0.14
-60.70%
|
0.35
|
| Interest Expense |
|
0.10
+1917.62%
|
0.01
-50.00%
|
0.01
|
| Interest Income Non Operating |
|
0.03
-82.04%
|
0.14
-60.40%
|
0.36
|
| Interest Income |
|
0.03
-82.04%
|
0.14
-60.40%
|
0.36
|
| Other Income Expense |
|
—
|
-0.97
-20936.34%
|
0.00
|
| Other Non Operating Income Expenses |
|
—
|
0.08
+1560.56%
|
0.00
|
| Gain On Sale Of Security |
|
—
|
-0.00
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-3.85
+20.76%
|
-4.86
+41.37%
|
-8.28
|
| Net Income From Continuing Operation Net Minority Interest |
|
-3.85
+20.76%
|
-4.86
+41.37%
|
-8.28
|
| Net Income From Continuing And Discontinued Operation |
|
-3.85
+20.76%
|
-4.86
+41.37%
|
-8.28
|
| Net Income Continuous Operations |
|
-3.85
+20.76%
|
-4.86
+41.37%
|
-8.28
|
| Normalized Income |
|
-3.85
-0.93%
|
-3.81
+53.97%
|
-8.28
|
| Net Income Common Stockholders |
|
-3.85
+20.76%
|
-4.86
+41.37%
|
-8.28
|
| Diluted EPS |
|
—
|
-0.35
+41.37%
|
-0.59
|
| Basic EPS |
|
—
|
-0.35
+41.37%
|
-0.59
|
| Basic Average Shares |
|
—
|
13.94
+0.00%
|
13.94
|
| Diluted Average Shares |
|
—
|
13.94
+0.00%
|
13.94
|
| Diluted NI Availto Com Stockholders |
|
-3.85
+20.76%
|
-4.86
+41.37%
|
-8.28
|
| Depreciation Amortization Depletion Income Statement |
|
0.00
-26.44%
|
0.01
-45.52%
|
0.01
|
| Depreciation And Amortization In Income Statement |
|
0.00
-26.44%
|
0.01
-45.52%
|
0.01
|
| Depreciation Income Statement |
|
0.00
-26.44%
|
0.01
-45.52%
|
0.01
|
| Insurance And Claims |
|
—
|
0.08
-0.97%
|
0.08
|
| Line Item | Trend | 2025-12-31 |
|---|---|---|
| Total Assets |
|
0.48
|
| Current Assets |
|
0.31
|
| Cash Cash Equivalents And Short Term Investments |
|
0.24
|
| Cash And Cash Equivalents |
|
0.24
|
| Other Short Term Investments |
|
—
|
| Other Current Assets |
|
0.07
|
| Total Non Current Assets |
|
0.18
|
| Net PPE |
|
0.17
|
| Gross PPE |
|
0.24
|
| Accumulated Depreciation |
|
-0.07
|
| Machinery Furniture Equipment |
|
0.07
|
| Other Properties |
|
0.16
|
| Other Non Current Assets |
|
0.01
|
| Total Liabilities Net Minority Interest |
|
2.45
|
| Current Liabilities |
|
2.41
|
| Payables And Accrued Expenses |
|
0.79
|
| Payables |
|
0.38
|
| Accounts Payable |
|
0.38
|
| Current Accrued Expenses |
|
0.40
|
| Current Debt And Capital Lease Obligation |
|
1.62
|
| Current Debt |
|
1.50
|
| Current Capital Lease Obligation |
|
0.12
|
| Total Non Current Liabilities Net Minority Interest |
|
0.04
|
| Long Term Debt And Capital Lease Obligation |
|
0.04
|
| Long Term Capital Lease Obligation |
|
0.04
|
| Stockholders Equity |
|
-1.96
|
| Common Stock Equity |
|
-1.97
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
13.98
|
| Ordinary Shares Number |
|
13.94
|
| Treasury Shares Number |
|
0.05
|
| Additional Paid In Capital |
|
51.53
|
| Retained Earnings |
|
-53.35
|
| Treasury Stock |
|
0.15
|
| Total Equity Gross Minority Interest |
|
-1.96
|
| Total Capitalization |
|
-1.96
|
| Working Capital |
|
-2.10
|
| Invested Capital |
|
-0.47
|
| Total Debt |
|
1.66
|
| Net Debt |
|
1.26
|
| Capital Lease Obligations |
|
0.16
|
| Net Tangible Assets |
|
-1.96
|
| Tangible Book Value |
|
-1.97
|
| Current Notes Payable |
|
1.50
|
| Interest Payable |
|
0.10
|
| Preferred Stock Equity |
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Operating Cash Flow |
|
-1.94
+66.02%
|
-5.72
+16.03%
|
-6.82
|
| Cash Flow From Continuing Operating Activities |
|
-1.94
+66.02%
|
-5.72
+16.03%
|
-6.82
|
| Net Income From Continuing Operations |
|
-3.85
+20.76%
|
-4.86
+41.37%
|
-8.28
|
| Depreciation Amortization Depletion |
|
0.12
+1.17%
|
0.12
-1.98%
|
0.12
|
| Depreciation |
|
0.12
+1.17%
|
0.12
-1.98%
|
0.12
|
| Depreciation And Amortization |
|
0.12
+1.17%
|
0.12
-1.98%
|
0.12
|
| Stock Based Compensation |
|
1.35
+401.91%
|
0.27
-55.66%
|
0.61
|
| Operating Gains Losses |
|
—
|
0.00
|
—
|
| Gain Loss On Investment Securities |
|
—
|
0.00
|
—
|
| Change In Working Capital |
|
0.43
+136.08%
|
-1.19
-246.39%
|
0.81
|
| Change In Prepaid Assets |
|
0.02
+970.04%
|
-0.00
-149.30%
|
0.01
|
| Change In Payables And Accrued Expense |
|
0.52
+147.86%
|
-1.08
-219.16%
|
0.91
|
| Change In Accrued Expense |
|
0.30
+140.47%
|
-0.75
-187.77%
|
0.85
|
| Change In Payable |
|
0.21
+164.51%
|
-0.33
-711.72%
|
0.05
|
| Change In Account Payable |
|
0.21
+164.51%
|
-0.33
-711.72%
|
0.05
|
| Change In Other Current Assets |
|
—
|
0.00
+100.00%
|
-0.00
|
| Change In Other Current Liabilities |
|
-0.11
-6.13%
|
-0.11
-6.23%
|
-0.10
|
| Investing Cash Flow |
|
0.00
-100.00%
|
3.92
+203.71%
|
-3.78
|
| Cash Flow From Continuing Investing Activities |
|
0.00
-100.00%
|
3.92
+203.71%
|
-3.78
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.00
|
0.00
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.00
|
0.00
|
| Capital Expenditure |
|
—
|
-0.00
|
—
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
3.93
+203.76%
|
-3.78
|
| Purchase Of Investment |
|
0.00
+100.00%
|
-4.33
+61.06%
|
-11.13
|
| Sale Of Investment |
|
0.00
-100.00%
|
8.26
+12.46%
|
7.34
|
| Financing Cash Flow |
|
1.50
+3100.00%
|
-0.05
|
0.00
|
| Cash Flow From Continuing Financing Activities |
|
1.50
+3100.00%
|
-0.05
|
0.00
|
| Net Issuance Payments Of Debt |
|
1.50
|
0.00
|
—
|
| Issuance Of Debt |
|
1.50
|
0.00
|
—
|
| Short Term Debt Issuance |
|
1.50
|
0.00
|
—
|
| Net Short Term Debt Issuance |
|
1.50
|
0.00
|
—
|
| Net Common Stock Issuance |
|
0.00
+100.00%
|
-0.05
|
0.00
|
| Common Stock Payments |
|
0.00
+100.00%
|
-0.05
|
0.00
|
| Repurchase Of Capital Stock |
|
0.00
+100.00%
|
-0.05
|
0.00
|
| Changes In Cash |
|
-0.44
+75.94%
|
-1.85
+82.56%
|
-10.60
|
| Beginning Cash Position |
|
0.68
-73.08%
|
2.53
-80.73%
|
13.13
|
| End Cash Position |
|
0.24
-65.29%
|
0.68
-73.08%
|
2.53
|
| Free Cash Flow |
|
-1.94
+66.03%
|
-5.73
+16.01%
|
-6.82
|
| Interest Paid Supplemental Data |
|
—
|
0.00
-100.00%
|
0.00
|
| Amortization Of Securities |
|
0.00
+100.00%
|
-0.07
+13.07%
|
-0.08
|
| Change In Interest Payable |
|
0.10
+1917.62%
|
0.01
-44.49%
|
0.01
|
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|